• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Vickers Vantage Corp. I (Amendment)

    1/31/24 5:24:56 PM ET
    $VCKA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VCKA alert in real time by email
    SC 13D/A 1 d182136dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES & EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Scilex Holding Company

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    Common Stock - 80880W106

    (CUSIP Number)

    Jack Wu

    Sole Manager

    SCLX Stock Acquisition JV LLC

    960 San Antonio Road

    Palo Alto, CA 94303

    (650) 516-4310

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    November 30, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 13d-7(b) for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No.: 80880W106

     

     1.   

     NAME OF REPORTING PERSON

     

     SCLX Stock Acquisition JV LLC

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3.  

     SEC USE ONLY

     

     4.  

     SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

     SC

     5.  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Texas

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7.   

     SOLE VOTING POWER

     

     89,616,299 (1)

        8.  

     SHARED VOTING POWER

     

     0

        9.  

     SOLE DISPOSITIVE POWER

     

     89,616,299 (1)

       10.  

     SHARED DISPOSITIVE POWER

     

     0

    11.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     89,616,299 (1)

    12.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    13.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     38.2% (2)

    14.  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     OO

     

    (1)

    Comprised of (i) 60,068,585 shares of common stock, par value $0.0001 per share (“Common Stock”), of Scilex Holding Company (the “Issuer”), (ii) 29,057,097 shares of Series A Preferred Stock, par value $0.0001 per share, of the Issuer (“Series A Preferred Stock”) which are entitled to vote, together with the holders of Common Stock, and not separately as a class, on an as converted to Common Stock basis on all matters on which the holders of shares of Common Stock have the right to vote (with the number of votes being determined by dividing the stated value (as determined under the Issuer’s Certificate of Designations of Series A Preferred Stock, filed with the Delaware Secretary of State on November 10, 2022) by $10.00), and (iii) 490,617 shares of Common Stock issuable upon exercise of warrants exercisable within 60 days of the date on which this Schedule 13D has been filed with the Securities and Exchange Commission (“SEC”).

    (2)

    Percent of class beneficially owned is calculated based on 157,905,655 shares of Common Stock outstanding as of November 30, 2023, plus 490,617 shares of Common Stock issuable upon exercise of warrants exercisable within 60 days of the date on which this Schedule 13D has been filed with the SEC. Shares of Series A Preferred Stock are not convertible into shares of Common Stock and therefore the 29,057,097 shares of Series A Preferred Stock held by the Reporting Person are not included in this percentage. The Reporting Person’s aggregate voting power, including shares of Series A Preferred Stock and assuming the exercise of all warrants held by the Reporting Person, is 47.81%.

     

    - 2 -


    Explanatory Note

    This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (“SEC”) on September 29, 2023 (the “Schedule 13D”), relating to the common stock, par value $0.0001 per share (“Common Stock”) of Scilex Holding Company, a Delaware corporation (the “Issuer”). Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used herein without definition shall have the meaning set forth in the Schedule 13D. This Amendment No. 1 was triggered solely due to a change in the number of outstanding shares of Common Stock of the Issuer.

     

    ITEM 5.

    Interest in Securities of the Issuer.

     

    (a)

    See responses to Items 11 and 13 on the cover page.

     

    (b)

    See responses to Items 7, 8, 9 and 10 on the cover page.

     

    (c)

    The Reporting Person has not effected any transactions of Common Stock or Series A Preferred Stock during the 60 days preceding the date of this report.

     

    (d)

    Not applicable.

     

    (e)

    Not applicable.

     

    ITEM 7.

    Material to be Filed as Exhibits.

    Item 7 of the Schedule 13D is hereby amended and supplemented as follows:

     

    Exhibit
    Number
      

    Description

    4    Power of Attorney, dated as of January 31, 2024.

     

    - 3 -


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: January 31, 2024

     

    SCLX STOCK ACQUISITION JV LLC
    By:  

    /s/ Stephen Ma, as Attorney-in-Fact

    Name:   Stephen Ma
    Title:   Attorney-in-Fact for Jack Wu, Sole Manager
    Get the next $VCKA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VCKA

    DatePrice TargetRatingAnalyst
    More analyst ratings